WVE Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
2.3M
-94.1%
38.2M
+121.8%
17.2M
+126.7%
7.6M
-12.5%
8.7M
Cost of Revenue
0
0
0
0
0
Gross Profit
2.3M
-94.1%
38.2M
+121.8%
17.2M
+126.7%
7.6M
-12.5%
8.7M
Operating Expenses
76.1M
+9.4%
69.5M
-5.7%
73.7M
+15.2%
64.0M
+4.1%
61.5M
R&D
51.3M
+8.1%
47.4M
-10.2%
52.8M
+15.1%
45.9M
+5.5%
43.5M
SG&A
24.8M
+12.1%
22.1M
+5.8%
20.9M
+15.5%
18.1M
+0.5%
18.0M
Operating Income
-73802000
-135.8%
-31298000
+44.6%
-56467000
-0.2%
-56353000
-6.8%
-52759000
EBITDA
-72944000
-139.5%
-30457000
+45.2%
-55623000
-0.2%
-55497000
-6.9%
-51894000
Net Income
-69355000
-165.9%
-26087000
+50.9%
-53179000
+1.2%
-53852000
-6.7%
-50469000
EPS (Basic)
$-0.34
-161.5%
$-0.13
+55.2%
$-0.29
+9.4%
$-0.32
-3.2%
$-0.31
EPS (Diluted)
$-0.34
-161.5%
$-0.13
+55.2%
$-0.29
+9.4%
$-0.32
-3.2%
$-0.31
Shares (Diluted)
204.0M
+1.9%
200.2M
+11.0%
180.3M
+7.5%
167.7M
+2.3%
164.0M
Wave Life Sciences (WVE) โ€” Financials